Navigation Links
Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
Date:8/19/2008

NEW HAVEN, Conn., Aug. 19 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Pink Sheets: VION) announced today that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (the "HOVON") to conduct a clinical trial of laromustine (Cloretazine(R) (VNP40101M)) with standard remission-induction therapy in patients aged 18-65 with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplasia (MDS).

Alan Kessman, Chief Executive Officer, commented, "We are pleased to be working with HOVON, one of the most prestigious clinical groups in hematology oncology. We continue to believe that Cloretazine(R) will have broad utility in the treatment of hematological malignancies as both a single agent and in combination with other therapies. This trial will provide important data with regard to Cloretazine(R)'s utility in the treatment of AML when given in combination with standard remission-induction therapy for this devastating disease."

Dr. Bob Lowenberg, Chief Investigator of HOVON, said, "HOVON is focusing on the clinical development of new therapeutic options for patients with leukemia. Laromustine is a promising agent for that effort."

The trial has been designed as a Phase III study in two parts. Part A will determine the feasibility (based on safety and preliminary effectiveness) of laromustine administration at three possible dose levels in combination with cytarabine and idarubicin. Part A will also evaluate the pharmacokinetics and the clinical efficacy of the laromustine combination.

Part B is then designed to evaluate the clinical efficacy of the laromustine combination versus two cycles of cytarabine and idarubicin without laromustine with regard to clinical outcome ("event free survival"), the complete remission rate, disease free survival (DFS), risk of relapse and overall survival (OS), as well as the tolerance and toxicity, and pharmacokinetics of the combin
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
6. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
7. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
8. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 30, 2014 on Thursday, November 6, 2014, after the ... president and chief executive officer, will host a conference ... Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... of the conference call can be accessed through a ...
(Date:10/30/2014)... BOTHELL, Wash. , Oct. 30, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s third quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... Pharmaceuticals, a specialty pharmaceutical company based in Atlanta, ... the company as General Counsel and Chief Compliance ... and most recently held positions of increasing responsibility ... at Shionogi, Leslie built the company,s legal department ...
... Mass., Feb. 21, 2012 UV Flu Technologies, Inc. ... in its 1st quarter report, filed on February 16, 2012, ... for the last 12 months, with another 20% reduction in ... sales and gross profits.  On February 3, 2012, the Company ...
Cached Medicine Technology:Leslie Zacks Joins Arbor Pharmaceuticals as General Counsel and Chief Compliance Officer 2UV Flu Technologies Continues Progress on Numerous Fronts 2UV Flu Technologies Continues Progress on Numerous Fronts 3
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... 30, 2014 REV'D Provision Co. announced ... available through a unique service called, The Feed ... empower the everyday athlete. The Feed has taken the ... created a system to pass that information on to ... is now available on The Feed!” says REV’D® marketing ...
(Date:10/30/2014)... October 30, 2014 Victory Healthcare, ... its 2014 third quarter infection rates and patient ... infection rates of only two percent or less, ... scores exceeding 98 percent. , “We are delighted ... included rising satisfaction scores,” said Robert Helms, chairman ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Scientists who used stem ... say their breakthrough could provide a new way to ... diseases. The team used human pluripotent stem cells ... the body -- to grow the functional miniature stomachs, ... a major cause of ulcers and stomach cancer. ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Many U.S. ... campus, even though tanning increases the risk for ... among young adults, particularly white women, so colleges ... health, the researchers said. "Public health efforts ... population awareness of the harms that indoor tanning ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... WASHINGTON, Sept. 23 Speaker Nancy Pelosi delivered opening remarks ... Day Summit" this morning in the Capitol Visitor,s Center. Below are ... , "Thank you, Chairwoman Barbara Lee for your leadership ... , , "Essential to the CBC,s efforts ...
... , SAN FRANCISCO, Sept. 23 ... Convention to be held at the Santa Clara Marriot from ... Founded in 1998, FA is an international fellowship of individuals ... addiction. For many people who use food as a drug, ...
... release pills and capsules that show a tendency in the ... in a faster and potentially unsafe manner in patients who ... until proven safe with testing in people. That,s the ... issue of ACS, Molecular Pharmaceutics , a bi-monthly journal. ...
... , , WASHINGTON, Sept. 23 ... Americans are reporting stress attributed to financial concerns despite rising unemployment ... (APA). , , In a poll surveying ... 2009, 75 percent of adults reported that the economy caused stress ...
... , , PRINCETON, N.J., Sept. ... buy and carry condoms, the makers of Trojan(R) Brand Condoms recently ... and discreet plastic case. The new product, which is designed to ... the checkout counters of many food, drug and convenience retail locations, ...
... , NORTHRIDGE, Calif., Sept. 23 Today, Nature ... Your Greatness(TM) contest. Nature Made is the nation,s best-selling ... drug, mass and club channels. The company celebrates the inherent ... year, challenged Americans to submit their personal stories of greatness ...
Cached Medicine News:Health News:Pelosi Remarks at the Congressional Black Caucus Foundation's Annual Legislative Conference 2Health News:Pelosi Remarks at the Congressional Black Caucus Foundation's Annual Legislative Conference 3Health News:Food Addicts Convention Draws 800 Members from 31 States, 5 Nations Around the World 2Health News:Food Addicts Convention Draws 800 Members from 31 States, 5 Nations Around the World 3Health News:Interview Alert: At Anniversary of Financial Meltdown, Psychologists Notice Downward Trends in Economic Stress 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 3Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 4Health News:National 'Greatness' Contest Winners Announced 2Health News:National 'Greatness' Contest Winners Announced 3
... Titanium Cranial Fixation Systems incorporate a ... requested by surgeons and surgical staff. ... may be either shaped on the ... a pre-measured, cut, bent and shaped ...
Specially designed combination of demineralized bone fibers and demineralized bone cubes that are both osteoinductive and osteoconductive. Packs well into bone defects. Eliminates the need to mix can...
... matrix and conductive cancellous chips. ... be free of foreign matter. ... is 125 to 1000 . ... 1 - 8 mm. 5:3 ...
Demineralized cortical fibers and cancellous chips....
Medicine Products: